Vascular targeting agents

Current Oncology Reports

Volumn 6, Issue 2, 2004, Pages 103-110

  Pilat, Mary Jo ^a   McCormick, Julie ^a   LoRusso, Patricia Mucci ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANGIOGENESIS INHIBITOR; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; AVE 8062A; BLEOMYCIN; CISPLATIN; COLCHICINE; COMBRETASTATIN A4 PHOSPHATE; CONTRAST MEDIUM; CYTOTOXIC AGENT; FLAVONOID; GADOLINIUM; MITOFLAXONE; MITOFLAXONE 2 DIETHYLAMINOETHYL ESTER; MONOCLONAL ANTIBODY HUJ591; N ACETYLCOLCHINOL PHOSPHATE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NSC 640888; PACLITAXEL; PHOSPHATIDYLSERINE INHIBITOR; PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITOR; THALIDOMIDE; TISSUE FACTOR PATHWAY INHIBITOR; TUBULIN BINDING AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1 INHIBITOR; VASCULAR TARGETING AGENT; VASCULOTROPIN; VINBLASTINE; VINCRISTINE; TUBULIN; TUBULIN MODULATOR;

ALOPECIA; ANEMIA; ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANXIETY; ATAXIA; BONE MARROW SUPPRESSION; BRONCHOSPASM; CANCER PAIN; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DEGRADATION; DRUG DESIGN; DRUG ERUPTION; DRUG POTENTIATION; DRUG STRUCTURE; DYSPNEA; ECG ABNORMALITY; FATIGUE; FLUSHING; HEADACHE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; ILEUS; INTESTINE ISCHEMIA; LEUKOPENIA; LIVER TOXICITY; LUNG TOXICITY; LYMPHOCYTOPENIA; MONOTHERAPY; MOTOR NEUROPATHY; MYALGIA; NAUSEA; NEPHROTOXICITY; NONHUMAN; OBSTRUCTIVE JAUNDICE; PAIN; PERIPHERAL NEUROPATHY; QT PROLONGATION; REVIEW; SEDATION; SLURRED SPEECH; SOLID TUMOR; SOMNOLENCE; SYNCOPE; TREMOR; TUMOR BLOOD FLOW; TUMOR NECROSIS; TUMOR VASCULARIZATION; URINE INCONTINENCE; URTICARIA; VISUAL DISORDER; VOMITING; DRUG EFFECT; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUBULIN; TUBULIN MODULATORS;

EID: 2342564355     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-004-0021-6     Document Type: Review

References (56)

1. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
2. Siemann DW: Vascular targeting agents: horizons in cancer therapeutics: from bench to bedside 2002, 3:4-15.
3. Chiu RK, Lambin P: Hypoxia as a target for combined modality treatments. Eur J Cancer 2002, 38:240-257.
4. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
5. Burke PA, DeNardo SJ: Antiangiogenic agents and their promising potential in combined therapy. Crit Rev Oncol Hematol 2001, 39:155-171.
6. Varner JA, Cheresh DA: Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. In Important Advances in Oncology. Edited by DeVita VT, Hellman S, Rosenbery SA. Philadelphia: Lippincott-Raven; 1996:69-87.
7. Anderson HL, Yap JT, Miller MP, et al.: Assessment of pharmacodynamic vascular response in a phase I trial of combrestatin A4 phosphate. J Clin Oncol 2003, 21:2823-2830.
8. Remick SC: Vascular targeting: clinical experience: horizons in cancer therapeutics: from bench to bedside 2002, 3:16-23.
9. Denekamp J: Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 1990, 9:267-282.
10. Thorpe PE, Chaplin DJ, Blakey DC: The first international conference on vascular targeting: meeting overview. Cancer Res 2003, 63:1144-1147.
11. Chaplin DJ, Hill SA: The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Radiat Oncol Biol Phys 2002, 54:1491-1496.
12. Walsh: The Anatomy, Physiology, Pathology and Treatment of Cancer. London: 1844.
13. Wolfrum WH: A critique of tumor resistance. J Cancer Res 1923, 7:283-31.
14. Blakey DC, Ashton SE, Westwood FR, et al.: ZD6126: a novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 2002, 54:1497-1502.
15. Huang X, Molema G, King S, et al.: Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997, 275:547-550.
16. Chang SS, Reuter VE, Heston WD, et al.: Five different antiprostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated vasculature. Cancer Res 1999, 59:3192-3198.
17. Milowsky MI, Rosmarin AS, Cobham MV, et al.: Anti-PSMA mAB huJ591 specifically targets tumor vascular endothelial cells with advanced solid tumor malignancies [abstract]. Proc ASCO 2002, 21:29.
18. Ludford RJ: Colchicine in the experimental chemotherapy of cancer. J Natl Cancer Inst 1945, 6:89-101.
19. Carswell EA, Old LJ, Kassel RL, et al.: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975, 25:3666-3670.
20. Baguley BC, Ching LM: DMXAA: an antivascular agent with multiple host responses. Int J Radiat Oncol Biol Phys 2002, 54:1503-1511.
21. Mahadevan V, Malik ST, Meager A, et al.: Role of tumor necrosis factor in flavone acetic acid-induced tumor vascular shutdown. Cancer Res 1990, 50:5537-5542.
22. Kerr DJ, Kaye SB, Graham J, et al.: Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester). Cancer Res 1986, 46:142-146.
23. Kerr DJ, Kaye SB, Cassidy J, et al.: Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res 1987, 47:6776-6781.
24. Bibby MC, Double JA: Flavone acetic acid: from laboratory to clinic and back. Anticancer Drugs 1993, 4:3-17.
25. Galbraith SM, Rustin GJS, Lodge MA, et al.: Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002, 20:3826-3840.
26. Rewcastle GW, Atwell GJ, Baguley BC, et al.: Potential antitumor agents. 63. Structure-activity relationships for side-chain analogues of colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid. J Med Chem 1991, 34:2864-2870.
27. Pedley RB, Boden JA, Boden R, et al.: Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res 1996, 56:3293-3300.
28. Siemann DW, Mercer E, Lepler S, et al.: Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002, 99:1-6.
29. Ching LM, Joseph WR, Crosier RE, et al.: Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res 1994, 54:870-872.
30. Philpott M, Joseph WR, Crosier KE, et al.: Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Br J Cancer 1997, 76:1586-1591.
31. Jameson MB, Thompson PI, Baguley BC, et al.: Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 2003, 88:1844-1850.
32. Wilson WR, BC Baguley: Combination of the antivascular agent DMXAA with radiation and chemotherapy. Int J Radiat Oncol Biol Phys 2000, 46:706.
33. Siim BG, Pruijn FB, Shalal-Zwain S, et al.: Marked potentiation of the antitumour activity of chemotherapy drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 2003, 51:43-52.
34. Cliffe S, Taylor ML, Rutland M, et al.: Combining bioreductive drugs (SR4233 or SN23862) with the vasoreactive agents flavone acetic acid or 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys 1994, 24:373-377.
35. Lash CJ, LI AE, Rutland M, et al.: Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination wit h5-hydroxytryptamine and bioreductive drugs. Br J Cancer 1998, 78:439-445.
36. Pedley RB, El-Emir E, Flynn A, et al.: Synergy between vascular targeting agents and antibody-directed therapy. Int J Radiat Oncol Biol Phys 2002, 54:1524-1531.
37. Cao Z, Joseph WR, Browne WL, et al.: Thalidomide increases both intra-tumoral tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1999, 80:716-723.
38. Kanwar JR, Danwar RK, Pandey S, et al.: Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to eradication of large tumors and multiple tumor foci. Cancer Res 2001, 61:1948-1956.
39. Dorr T: Dvorakova K, Snead K, et al.: Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor. Invest New Drugs 1996, 14:131-137.
40. Rustin GJS, Galbraith SM, Anderson H, et al.: Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003, 21:2815-2822.
41. Horsman MR, Ehrnrooth E, Laderkarl M, et al.: The effect of combretastatin A-4 phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys 1998, 42:895-989.
42. Dark GG, Hill SA, Prise VE, et al.: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997, 57:1829-1834.
43. Iyer S, Chaplin DJ, Rosenthal DS, et al.: Induction of apoptosis in proliferating human endothelial cells by tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res 1998, 58:4510-4514.
44. Malcontenti-Wilson C, Muralidharan V, Skinner S, et al.: Combretastatin A4 prodrug study of effect on the growth and microvasculature of colorectal liver metastases in a murine model. Clin Cancer Res 2001, 7:1052-1060.
45. Chaplin DJ, Pettit GR, Hill SA: Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 1999, 19:189-195.
46. Dotwali A, Robertson K, Cooney M, et al.: A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002, 62:3408-3416.
47. Murata R, Overgaard J, Horsman MR: Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves the anti-tumor effects of hyperthermia, radiation and mild hyperthermia. Int J Radiat Oncol Bio Phys, 2002, 51:1018-102.
48. Galbraith SM, Maxwell RJ, Lodge MA, et al.: Combrestatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2003, 21:2831-2842.
49. Tolcher AW, Forero L, Celio P, et al.: Phase I, pharmacokinetic and DCE-MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28 days [abstract]. Proc ASCO, 2003, 22:834.
50. Lejeune P, Hodge TG, Vrignaud P, et al.: In vivo antitumor activity and tumor necrosis induced by AVE8062A, a tumor vasculature targeting agent. Presented at the 93rd annual conference of the American Association for Cancer Research. April 6-10, 2002, San Francisco, CA; abstract 781.
51. Blakey DC, Westwood FR, Walker M, et al.: Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002, 8:1974-1983.
52. Gadgeel SM, LoRusso PM, Wozniak AJ, et al.: A dose escalation study of the novel vascular targeting agent, ZD6126 in patients with solid tumors [abstract]. Proc ASCO 2002, 21:438.
53. Radema SA, Beerepoot LV, Wittevee PO, et al.: Clinical evaluation of the novel vascular-targeting agent, ZD6126: assessment of toxicity and surrogate markers of vascular damage [abstract]. Proc ASCO 2002, 21:439.
54. DelProposto Z, LoRusso P, Latif Z, et al.: MRI evaluation of the effect of the vascular targeting agent ZD6126 on tumor vasculature [abstract]. Proc ASCO 2002, 21:440.
55. Hande KR, Meek K, Lockhart AC, et al.: Pharmacokinetics and safety profile of ABT-751, a novel microtubulin inhibitor [abstract]. Proc ASCO 2003, 22:520.
56. Luo Y, Mohning KM, Nuss ME, et al.: A novel anti-tubulin agent (ABT-751) selectively reduces tumor perfusion in a subcutaneous rat tumor model as measured by MRI. Presented at the 93rd annual conference of the American Association for Cancer Research. April 6-10, 2002, San Francisco, CA; abstract 784.